DrugPatentWatch Database Preview
Details for Patent: 7,396,841
Which drugs does patent 7,396,841 protect, and when does it expire?
Patent 7,396,841 protects PREVACID IV and is included in one NDA.
Protection for PREVACID IV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has six patent family members in five countries.
This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,396,841
| Title: | Injections |
| Abstract: | An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent. |
| Inventor(s): | Doen; Takayuki (Suita, JP), Nagao; Masao (Kashiba, JP), Asakawa; Naoki (Takatsuki, JP), Takechi; Nobuyuki (Osaka, JP) |
| Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Application Number: | 10/344,805 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Formulation; Process; Use; |
Drugs Protected by US Patent 7,396,841
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Na | PREVACID IV | lansoprazole | INJECTABLE;INTRAVENOUS | 021566-001 | May 27, 2004 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,396,841
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2000-248468 | Aug 18, 2000 |
| PCT Information | |||
| PCT Filed | August 17, 2001 | PCT Application Number: | PCT/JP01/07075 |
| PCT Publication Date: | February 28, 2002 | PCT Publication Number: | WO02/15908 |
International Family Members for US Patent 7,396,841
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 7875501 | Start Trial | |||
| Canada | 2419067 | Start Trial | |||
| European Patent Office | 1310252 | Start Trial | |||
| Japan | 2002128675 | Start Trial | |||
| Japan | 4136340 | Start Trial | |||
| World Intellectual Property Organization (WIPO) | 0215908 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
